A pathogenetic role of OH in myocardial stunning has been inferred from the protective effects of OH scavengers and iron chelators. However, conclusive demonstration of the OH radical hypothesis of myocardial stunning requires direct verification of three major, but still unproven, assumptions: (1) OH is produced in the stunned myocardium in vivo; (2) antioxidant therapy inhibits OH production; and (3) such inhibition results in enhanced recovery of contractility (ie, OH is necessary for the development of myocardial stunning). Since phenylalanine (Phe) reacts with OH to form the hydroxylated products ortho-, meta-, and para-tyrosines (o-, m-, and p-tyr), we used aromatic hydroxylation of Phe to detect OH formation in the stunned myocardium. Open-chest dogs undergoing a 15-minute coronary occlusion followed by reperfusion received an intravenous infusion of Phe (54.3 mg/kg for 11.5 minutes beginning 90 seconds before reperfusion); these animals were given either no antioxidant therapy (group I, n=15), N-2-mercaptopropionyl glycine (MPG) (group II, n=11), or MPG combined with superoxide dismutase, catalase, and desferrioxamine (group III, n=12). In addition, group IV (nonischemic control group, n=6) received Phe but did not undergo coronary occlusion, whereas group V (ischemic control group, n=16) underwent a 15-minute occlusion but did not receive Phe or antioxidants. The plasma concentrations of tyrosines in the local venous effluent and in the arterial blood were measured with high-performance liquid chromatography. In group I, production of o-and m-tyr, which are specific markers of OH formation, began during coronary occlusion but increased dramatically immediately after reperfusion, peaking at 1 minute and continuing up to 10 minutes of reperfusion. In group II, the production of oand m-tyr was markedly decreased throughout the first 10 minutes of reperfusion. In group III, the production of m-tyr was decreased to levels similar to those in group II, whereas the production of o-tyr was almost completely abolished. There was no appreciable production of o-or m-tyr in group IV. Recovery of contractile function (assessed as systolic wall thickening) was increased in group I vs group V. Recovery of function was further enhanced in group II, with only a slight additional improvement in group III. This study demonstrates that (1) -OH is produced in the stunned myocardium in vivo after brief regional ischemia, (2) antioxidants, such as MPG or MPG combined with superoxide dismutase, catalase, and desferrioxamine, actually inhibit OH activity in vivo, (3) this inhibition results in attenuation of myocardial stunning, (4) there is an inverse relation between the magnitude of the inhibition of OH activity soon after reflow and the severity of the subsequent contractile dysfunction, and (5) Phe, which itself acts as an OH scavenger, attenuates postischemic dysfunction. These results provide direct evidence that OH is an important mediator of myocardial stunning and suggest that aromatic hydroxylation of Phe may be a useful technique to investigate the role of OH in intact animals or in humans.
amine.6-1' However, the evidence provided by these studies2-1" is indirect and, therefore, inconclusive. Formation of *OH in stunned myocardium in intact animals has not yet been demonstrated. The very occurrence of a Haber-Weiss reaction in intact animals continues to be questioned.12"3 Furthermore, the ability of putative "anti--OH" interventions (such as dimethylthiourea, MPG, and desferrioxamine) to actually decrease *OH activity in vivo has not been documented, so one cannot rule out the possibility that the beneficial effects of these antioxidants are due to nonspecific actions. Further investigation is required to overcome these limitations. In particular, to unequivocally establish a pathogenetic role of -OH in myocardial stunning, it is necessary to directly measure -OH production in the stunned myocardium in the presence and absence of antioxidant interventions and to demonstrate a correlation between the amount of -OH produced and the severity of postischemic dysfunction. Measurement of -OH formation in biological systems is difficult because *OH is highly reactive with most organic molecules (with rate constants of 109 to 1010 M`* s-') and its lifetime in biological matrices is extremely short (<-1 nanosecond).'4"5 Currently, the two most promising methods to measure *OH in vivo are spin trapping and aromatic hydroxylation. The spin trap 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) has been used to detect -OH in isolated hearts,16-23 but the applicability of this technique to the in vivo setting has not been demonstrated. In unpublished studies, we have been unable to detect formation of -OH adducts of DMPO in our open-chest dog model of stunned myocardium because of the presence of spurious signals associated with DMPO. Therefore, we have developed a different approach based on the technique of aromatic hydroxylation. The theoretical rationale for using this technique is the propensity of -OH to attack aromatic compounds, leading to the formation of hydroxylated derivatives that can be detected and quantitated even at minute concentrations.1524-3' The aromatic compound salicylate has been successfully used to study -OH formation in isolated hearts subjected to ischemia and reperfusion and has provided important insights into the free radical reactions associated with restoration of flow. 32 the systems under investigation. For example, it inhibits cyclooxygenase and thereby interferes with the production of prostaglandins. The cyclooxygenase pathway is a potential source of free radicals during ischemia and reperfusion,36 and prostaglandins appear to modulate ischemia/reperfusion injury as well as myocardial stunning. 37 Salicylate also inhibits phospholipase C38 and forms complexes with several metal ions. Furthermore, in pilot studies we attempted to use salicylate in our in vivo model of myocardial stunning, but because of toxic effects (mainly ventricular fibrillation), we were unable to administer doses that resulted in plasma concentrations sufficiently high (millimolar range)26 to detect .OH. Therefore, we decided to use phenylalanine (Phe) as an alternative detector molecule. Previous studies in vitro28'29 have demonstrated that Phe reacts with -OH to form hydroxylated products (ortho-, meta-, and paratyrosines [o-, m-, and p-tyr]) ( Fig 1) and that the measurement of these products can be used as a sensitive assay for the production of *OH in biological systems. [39] [40] [41] In whole animals or organs, p-tyr is not particularly useful as a marker of -OH because it is a normal metabolite of Phe, produced by the enzyme Phe hydroxylase.39'42 However, since o-and m-tyr are not thought to be normal metabolites of Phe,15'3"39-43 the formation of o-and m-tyr can be used as an index of *OH formation.1'531' [39] [40] [41] The overall objective of this study was to directly investigate, using aromatic hydroxylation of Phe, the role of *OH in the pathogenesis of myocardial stunning in the anesthetized dog. The specific objectives were to determine (1) whether -OH is produced in the stunned myocardium, (2) if so, whether the production of *OH is inhibited by antioxidants, and (3) if so, whether such inhibition mitigates myocardial stunning. An additional goal was to develop a model that allows quantitative assessment of -OH production in vivo.
Materials and Methods
A total of 79 dogs were used. This study was performed in accordance with the guidelines of the Committee on Animals of Baylor College of Medicine and with the "Guide for the Care and Use of Laboratory Animals" (National Institutes of Health publication No. 80-23).
Experimental Preparation
The experimental preparation has been previously described in detail.2 4684445 Briefly, mongrel dogs of either sex (15 to 35 kg) were anesthetized with sodium pentobarbital (35 mg/kg IV), ventilated with room air, and instrumented with a snare and a Doppler flow probe around the mid left anterior descending coronary artery (LAD), with epicardial Doppler wall thickening probes in the center of the region to be rendered ischemic and in the posterior (control) left ventricular (LV) wall, with catheters in the aorta and left atrium, and with a 6F pressure transducer (Millar Instruments, Houston, Tex) in the LV cavity through an apical stab wound. For intracoronary infusion of MPG, a 27-gauge needle connected to a lymphangiographic catheter44 was introduced into the LAD, just distal to the snare. To prevent clotting, heparin was given immediately after insertion of the needle (3000 U IV) and continuously thereafter (500 U/h). An 8F Sones catheter was introduced into the coronary sinus and advanced into the anterior interventricular vein. In its final position, the tip of the catheter was at least 0.5 cm distal to the snare, so that any contamination of blood samples with venous effluent from other vascular beds was minimized. 4, 8, 44, 45 Particular care was taken to ensure that fundamental physiological parameters were within normal limits for the entire duration of the protocol. Only dogs with a hematocrit of >30% were admitted to the study. Supplements of potassium chloride (20 mEq) were given intravenously to maintain plasma potassium concentration in the range of 4.0 to 5.0 mEq/L.6 The rate of fluid replacement was standardized at approximately 80 mL of normal saline/h.44 Throughout the study, body temperature was kept within physiological limits by adjusting a heating blanket, while arterial pH and Po2 were maintained in the normal range by adjusting the ventilatory parameters. 6 L-Phe (Sigma Chemical Co, St Louis, Mo) was dissolved in normal saline at a concentration of 15 mg/mL and infused intravenously beginning 90 seconds before coronary reperfusion and continuing until 10 minutes after reperfusion (total dose, 54.3 mg/kg; total volume of solution infused, 3.6 mL/kg). From 90 seconds before reperfusion to 30 seconds after reperfusion, Phe was infused at a dose of 12.4 mg* kg.* min`. After 30 seconds of reperfusion, the infusion rate was decreased to 3.1 mg * kg-1 * min-m , which was continued until 10 minutes after reperfusion. This combination of an initial fast infusion followed by a slower infusion was designed to rapidly raise plasma levels of Phe just before release of the occlusion and to maintain such elevated levels for the first 10 minutes of reperfusion (the time interval during which the production of OH would be expected to be most intense16-22). Our infusion rates were selected on the basis of pilot studies demonstrating that this protocol led to a twofold to threefold increase in plasma concentration of Phe during the first few minutes of reperfusion. Higher doses could not be used because they were found to cause hypotension. We selected the intravenous route (as opposed to the intracoronary route) in an effort to achieve relatively uniform coronary arterial plasma concentrations of Phe in different dogs; this would have been difficult to achieve with an intracoronary infusion because of the marked (and unpredictable) variations in coronary flow during ischemia and reperfusion. Dogs were assigned to one of the following five groups.
Group I
Group I (Phe only) received Phe as described above.
Group II
Group II (Phe+MPG) was given Phe as in group I; in addition, these dogs received an intracoronary infusion of MPG at a dose of 8 mg . kg`h-1 starting 15 minutes before coronary occlusion and ending 2 hours after reperfusion. This dosage has been previously found to markedly attenuate postischemic dysfunction as well as production of spin-trapped radicals in this experimental model.4 MPG (Sigma) was dissolved at a concentration of 10 mg/mL in a mixture of 77% heparinized normal saline and 23% water, so that the infusate was isosmotic with the plasma (osmolality, 280 mOsm/kg). The volume of solution infused averaged 0.33 mL/min (range, 0.20 to 0.47 mL/min). Before and after MPG administration, the LAD was infused with an equivalent volume of vehicle.
Group III
Group III (Phe+combination antioxidant therapy) was given Phe as in groups I and II; in addition, these dogs received intravenous infusions of superoxide dismutase (SOD), catalase, desferrioxamine, and MPG. SOD and catalase were given as a continuous infusion starting 15 minutes before coronary occlusion and ending 30 minutes after reperfusion (total dose, 16 000 U/kg for SOD and 100 000 U/kg for catalase). The enzymes were dissolved in normal saline and infused at a rate of 0.5 mL/min. Human CuZn-SOD (expressed in yeast cells by recombinant DNA technology46) was obtained courtesy of the Pharmacia-Chiron Partnership, Emeryville, Calif (specific activity, 3200 U/mg protein). With the use of physicochemical and biochemical criteria, this enzyme has been proven to be identical to human CuZn-SOD.47 Catalase (Sigma) was purified from bovine liver (specific activity, 48 900 U/mg protein). Desferrioxamine mesylate (Desferal, CIBA Pharmaceutical Co, Summit, NJ) was infused at a rate of 13.3 mg -kg-' h`1 beginning 60 minutes before LAD occlusion and continuing until 15 minutes of reperfusion (total dose, 20 mg/kg). To achieve the desired dose, 20 mg/kg desferrioxamine was dissolved in 45 mL normal saline, and this solution was infused at a rate of 0.5 mL/min. MPG was infused at a rate of 100 mg . kg`1 h`1 starting 60 minutes before coronary occlusion and continuing until 15 minutes after reperfusion (total dose, 150 mg/kg dissolved in 45 mL normal saline). The dosages of SOD, catalase, desferrioxamine, and MPG were similar to those previously found to attenuate myocardial stunning in the canine model. 6,7,48 53 Group IV Group IV (control group for tyrosine production) received Phe as in groups I, II, and III but did not undergo coronary occlusion. This control group was necessary to ensure that the production of tyrosines observed in groups I, II, and III was not the result of nonspecific effects of Phe unrelated to ischemia and reperfusion.
Group V Group V (control group for recovery of function) underwent the same experimental protocol as groups I, II, and III, except that no Phe and no antioxidants were administered. The reason for studying this control group was to determine whether the infusion of Phe in groups I, II, and III produced any beneficial effect on the recovery of contractile function in the stunned myocardium.
Experimental Protocol
The LAD was occluded for 15 minutes and reperfused for 4 hours. Regional myocardial blood flow was determined 10 minutes after occlusion with radioactive microspheres.54 Regional myocardial function was assessed as systolic wall thickening using a pulsed Doppler epicardial probe, as previously described. [2] [3] [4] 6, 8, 54 Briefly, the beginning and end of systole were determined from the onset of the rapid upstroke of the LV pressure tracing and the peak negative LV dP/dt, respectively.54 Percent systolic thickening fraction was calculated as the ratio of net systolic thickening to end-diastolic wall thickness, multiplied by 100.54 At least five beats were averaged at each time point, and all measurements were obtained at end expiration. At the end of the study, the size of the occluded/reperfused coronary vascular bed was determined by a postmortem dual-perfusion technique,6 whereby the previously occluded LAD was perfused with 1% triphenyltetrazolium chloride while the proximal LAD and the circumflex arteries were perfused with 0.5% Monastral blue dye.
Measurement of Tyrosines and Phe
By means of syringes containing 100 U heparin, blood samples (6 mL) were drawn over a 60-second period from the aorta or from the anterior interventricular vein and immediately centrifuged. After the addition of 20 ,gL concentrated HCl, the plasma samples were frozen at -70°C for subsequent analysis. Before analysis, the plasma samples were thawed at room temperature and then filtered through Centrifree micropartition devices (Amicon, Gloucestershire, UK) at 4000g for 3 hours at 20°C. The ultrafiltrates were then analyzed. The plasma concentration of isomeric tyrosines and of Phe was determined by high-performance liquid chromatography using ultraviolet (UV) detection. The technique has been described in detail elsewhere. 55 
Quantification of Myocardial Release of Tyrosines
Myocardial release of o-, m-and p-tyr at a specific time point was calculated by multiplying the transcardiac concentration gradient (ie, the difference between the coronary venous and the simultaneous arterial plasma concentration of tyrosines [in nanomoles per milliliter]) by the simultaneous coronary arterial blood flow (in milliliters per minute); this quantity was nor- Total number of dogs included in the study 15 11 12 6 16 Total number of dogs anesthetized 25 12 16 6 20 Number of dogs used for studies of tyrosine production 12 5 7 6 0
Number of dogs used for studies of regional function 12 7 7 6 16
Reasons for excluding from the analysis of regional function dogs that were used for tyrosine analysis Baseline thickening fraction < 10%
Number of dogs used for tyrosine analysis that were excluded from analysis of function
Number of dogs used for tyrosine analysis that were also used for analysis of function *One of these five dogs was excluded because of a large ischemic zone size (>35% of LV weight).
cumulative myocardial release of tyrosines over the first 10 minutes of reperfusion was calculated with a computerized program that integrates the measurements obtained at individual time points.48'44'45 Statistical Analysis All values are reported as mean±SEM. Differences among groups were analyzed by analysis of variance. If the F test showed an overall difference, comparisons of two means were performed with the two-tailed Student's t test for unpaired data, and the resulting P values were adjusted by the Bonferroni method.56 Myocardial release of tyrosines was analyzed by nonparametric methods (Kruskall-Wallis test and Wilcoxon signed rank test) because these data did not follow a normal distribution. 56 The changes in plasma Phe concentration between baseline and subsequent time points were evaluated with Student's t test for paired data using the Bonferroni correction.56 All statistical analyses were performed using the SAS software system.57
Results

Exclusions and Histochemical Analysis
Our major initial end point was the measurement of tyrosine production. For a variety of reasons (which are specified in the lower panel of Table 1 ), some of the dogs used to assess tyrosine production could not be used to assess recovery of contractile function. Conse-quently, we performed additional experiments for the specific purpose of measuring recovery of function (in these experiments tyrosines were not analyzed). Thus, in some dogs both tyrosine production and thickening fraction were measured, in others only tyrosine production was assessed, and in others only thickening fraction was measured. As a result, the sizes of groups I, II, and III in the studies of tyrosine production were different from the sizes of these groups in the studies of thickening fraction. The upper panel of Table 1 specifies the reasons for excluding dogs from any analysis (both from the studies of tyrosine production and from those of thickening fraction). (It should be noted that only a fraction of the dogs included were used for tyrosine measurements; the remainder were used for thickening measurements.) The lower panel of Table 1 indicates the reasons for excluding from the analysis of contractile function the dogs that were used for the analysis of tyrosine production.
The final analysis included 6 nonischemic control dogs (group IV) and 16 dogs in group V; in groups I, II, and III, the final analysis included 12, 5, and 7 dogs, respectively, in the studies of tyrosine production and 12, 7, and 7 dogs, respectively, in the studies of recovery of function. Because the composition of groups I, II, and III differed in the studies of tyrosine production and in those of recovery of function, hemodynamic variables, occluded bed size, and regional myocardial flow are reported separately for these two studies (see below). *These measurements were taken 2 minutes into the Phe infusion (at the end of the 12.4 mg-kg-1 . min`dose).
tThese measurements were taken at the end of the Phe infusion.
Tetrazolium staining confirmed the absence of irreversible injury in all dogs, which is consistent with numerous studies indicating that, in the dog, the damage associated with a 15-minute coronary occlusion is completely reversible.58
Arterial Blood Gases, Hematocrit, and Body Temperature Arterial pH, Po2, hematocrit, and esophageal temperature were within physiological limits in all groups throughout the experimental protocol (data not shown for the sake of brevity).
Studies of Tyrosine Production
Hemodynamic variables. Because the effects of intravenous Phe in intact animals have not been previously reported, particular care was taken to determine whether the dose used in this study exerted any toxic and/or nonspecific actions that would complicate the interpretation of the measurements of tyrosines and of the assessment of functional recovery. In group IV (control dogs that received Phe but did not undergo coronary occlusion), the infusion of Phe at the dose selected did not produce any appreciable effect on heart rate, arterial pressure, left atrial pressure, coronary blood flow, peak positive and negative LV dP/dt, and wall thickening in either the anterior or the posterior LV wall (Table 2 ). Moreover, after the infusion of Phe was begun, there were no consistent differences in systemic hemodynamics or wall thickening in the nonischemic region between groups I, II, and III (which received Phe) and group V (which did not receive Phe) (Tables 3 and 4 ). These results indicate that systemic administration of Phe at the dose used in this study is well tolerated in the dog, with no apparent cardiac toxicity or adverse hemodynamic effects.
The hemodynamic variables in the three groups that underwent LAD occlusion (groups I, II, and III) are summarized in Table 3 (for the sake of brevity, only heart rate, systolic arterial pressure, rate-pressure product, and peak positive LV dP/dt are reported). In general, all measured variables were similar in the three groups throughout the protocol.
Occluded bed size and regional myocardial blood flow.
The size of the occluded vascular bed was similar in groups I, II, and III (Table 5 ). There were no statistically significant differences among the three groups with respect to epicardial, endocardial, or mean transmural collateral blood flow to the ischemic zone (Table 5 ).
Arterial and venous levels of Phe. Coronary artery occlusion was associated with a nonsignificant increase in plasma Phe concentration in the coronary venous blood in groups I and II (Table 6 ), possibly because of the slower rate of removal of this amino acid during ischemia. Plasma Phe in the arterial blood did not change significantly during coronary occlusion. Administration of Phe produced an immediate increase in plasma Phe levels, such that 1 minute after reperfusion the arterial and venous concentrations of Phe were twofold to fourfold higher than at baseline in all three groups. Plasma levels of Phe remained elevated for the first few minutes of reperfusion and generally returned to values not significantly different from baseline by 20 minutes of reflow (10 minutes after the infusion of this amino acid was discontinued) ( Table 6 ). Thus, the dosage used in this study achieved the intended result of increasing the systemic levels of Phe during the first critical minutes of reflow. There were no significant differences in the arterial or venous plasma concentration of Phe between groups I and III at any time point during the protocol. Group II exhibited lower plasma levels of Phe than groups I and III at baseline and then again from 30 minutes of reperfusion until the end of the experiment ( Table 6 ). The reason for these differences is not clear, but it is important to note that neither the arterial nor the venous Phe concentration was significantly different in group II vis-a-vis groups I and III during the first 10 minutes of reperfusion (the time interval encompassing the burst of -OH production).
Myocardial production of tyrosines. As expected, the baseline (preischemic) plasma levels ofp-tyr were much higher than those of o-tyr and m-tyr. In groups I, II, III, and IV, respectively, the baseline concentrations of As indicated above, p-tyr is not a specific marker of .OH production, because it is normally produced by the enzyme Phe hydroxylase. Consequently, the changes in myocardial production of p-tyr must be interpreted differently from the changes in myocardial production of o-tyr and m-tyr. At baseline, a slight myocardial production ofp-tyr was observed in groups II and III (Fig 3) . In group I, reperfusion after the 15-minute LAD occlusion was associated with a marked increase in p-tyr production, which abated by 20 minutes. Although this increase was attenuated in groups II and III (which received antioxidant therapy), compared with group I the differences did not achieve statistical significance (Fig 3) . A low-level production of p-tyr continued during the remainder of the reperfusion phase (Fig 3) .
Different results were obtained with o-tyr and m-tyr, which are specific markers of *OH production. In con- (Figs 4 and 5 ). It is unlikely that the early burst of tyrosine release, which peaked at 1 minute, was caused solely by the use of a rapid infusion of Phe followed by a slow infusion, because in pilot studies (n=3) in which Phe was infused at a constant rate of 10 mg . kg`1 * min-1, beginning 5 minutes before coronary occlusion and ending 10 minutes after reperfusion, a burst of tyrosine release was noted after reflow with a similar time course. The marked decrease in tyrosine release noted in group I at 10 minutes of reperfusion cannot be ascribed to a decline in arterial levels of Phe because the arterial plasma concentration of this amino acid was similar at 5 and 10 minutes (0.69±0.19 and 0.64±0.18 mM, respectively [ Table 6 ]).
In group II, which received intracoronary MPG, the production of o-tyr and m-tyr was markedly decreased throughout the first 5 minutes of reperfusion as compared with group I (Figs 4 and 5 ). The differences were statistically significant at all time points except for the m-tyr release at 3 minutes of reflow. An even more striking effect was observed in group III, which received a combined intravenous infusion of multiple antioxidants (SOD, catalase, desferrioxamine, and MPG). In this group, the release of o-tyr was almost completely abolished (Fig 4) , and the release of m-tyr was decreased to levels similar to those noted in group II ( Fig  5) . The differences in o-tyr and m-tyr production between groups I and III were statistically significant at 1, 2, 3, 4, and 5 minutes. In addition, the production of o-tyr in group III was significantly (P<.05) less than that in group II at 1, 2, and 4 minutes of reperfusion. min-m g`in group I; change, -73.3%; P<.05). However, the administration of these antioxidants did not significantly change the production of p-tyr (P>.05 among the three groups). The cumulative production of o-tyr was significantly lower in group III as compared with group LI (P<.05), whereas the production of m-tyr did not differ between these two groups. In group IV, Phe was infused exactly as in groups I, II, and III, but no coronary occlusion was performed. Blood samples were obtained at times corresponding to those used in groups I, II, and III. As shown in Fig  7, in these dogs there was no appreciable myocardial production of o-tyr, m-tyr, or p-tyr at any time point during the infusion of Phe, ie, during the time interval corresponding to the first 10 minutes of reperfusion in groups I, II, and III (the production of o-tyr exhibited a minimal increase 1 hour after the end of Phe infusion, but this was caused by an increase in only one dog). The production of p-tyr (a normal enzymatic byproduct of Phe) increased in the late phase of the experiment (Fig 7) .
Studies of Regional Myocardial Function
The purpose of these studies was twofold. First, we sought to determine whether Phe intercepts OH radicals in a quantity sufficient to enhance the postischemic recovery of function. To this end, the dogs in group I, which received Phe, were compared with control dogs (group V) that did not receive Phe. Second, having observed that antioxidant therapy markedly inhibits tyrosine formation, we investigated whether this action results in attenuation of myocardial stunning. To this end, the dogs in group II (Phe+MPG) and group III (Phe+combined antioxidant therapy) were compared with the dogs in group I, which were given Phe only.
Of the 24 dogs that were included in the analysis of tyrosine production in groups I, II, and III, 11 were excluded from the analysis of regional myocardial func- 
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Repurfuslon tion for the reasons specified in the lower panel of Table  1 . An additional 3, 6, and 5 dogs were studied in groups I, II, and III, respectively, for the sole purpose of assessing regional function. Thus, a total of 12, 7, and 7 dogs were included in the analysis of regional function in groups I, II, and III, respectively. Hemodynamic variables. The hemodynamic variables in the four groups that underwent LAD occlusion (groups I, II, III, and V) are summarized in Table 4 . In general, all measured variables (heart rate, arterial pressure, rate-pressure product, left atrial pressure, and peak positive and negative LV dP/dt) were similar among the four groups throughout the protocol, with few exceptions. Compared with group V, group I exhibited greater heart rate, systolic arterial pressure, and rate-pressure product at baseline and greater heart rate during coronary occlusion; group II exhibited greater rate-pressure product at baseline; and group III exhibited greater systolic arterial pressure and rate-pressure product at baseline. (Since these differences were present before Phe infusion, ie, at baseline and during LAD occlusion, they cannot be ascribed to the administration of the amino acid.)
The size of the occluded vascular bed was similar in groups I, II, and V ( thing, should have limited the recovery of contractile ction in this group. There were no statistically sigzant differences among the four groups with respect :ndocardial, epicardial, or mean transmural collat-Iblood flow to the ischemic zone ( Table 5 ).
1 summary, the enhanced recovery of wall thickenobserved in groups I, II, and III vs group V cannot ascribed to differences in arterial blood gases, he-,ocrit, body temperature, systemic hemodynamics, luded bed size, or collateral flow. 'egional myocardialfunction. Systolic thickening fracin the nonischemic (control) region did not differ ificantly among groups I, II, and III at any time nt during the protocol (Table 4 ). In group V, the kening fraction was lower than in group I during D occlusion and at 2 hours of reperfusion and lower a in group III at 2 hours of reperfusion but did not er from group I, II, or III at most time points. 'aseline systolic thickening fraction in the region to rendered ischemic was 23.4±1.8% in group I, ;±2.1% in group II, 27.1±3.1% in group III, and ± 1.9% in group V (P=NS). During coronary occlu-1, the extent of paradoxical systolic thinning was also ilar in the four groups (Fig 8) . After reperfusion, trol dogs (group V) exhibited little recovery of tractile function, and 4 hours after restoration of v, the previously ischemic region was still dyskinetic, icating severe myocardial stunning (Fig 8) . In group Reperfusion I, however, which received Phe only, the recovery of wall thickening was greater than in the control group, with the differences achieving statistical significance at 3 hours (P<.01) and 4 hours (P<.01) of reperfusion ( Fig  8) . Thus, infusion of Phe, in itself, attenuated myocardial stunning. In group II, which received Phe plus intracoronary MPG, the recovery of wall thickening was further enhanced as compared with group I (Fig 8) .
Statistical analysis demonstrated that the measurements of thickening fraction in group IL were significantly greater than those in group V at all time points after reperfusion and significantly greater than those in group I at 2 hours of reflow. In group III, which received Phe + SOD + catalase + desferrioxamine + MPG, there appeared to be a slight additional improvement in the recovery of function (Fig 8) , but compared with group II ul CO) o -Tyrosine m-Tyrosine . In group I, reperfusion after the 15-minute left anterior descending coronary artery occlusion was associated with a burst of m-tyrosine production. The release of m-tyrosine peaked 1 minute after reperfusion and then declined substantially by 10 minutes. The production of m-tyrosine was markedly decreased in groups II and III. B indicates baseline; Occl, coronary occlusion.
Data are mean +SEM.
the differences were not statistically significant. Throughout the 4-hour observation period, the measurements of thickening fraction in group III were significantly higher than the corresponding values in groups V and I.
Discussion
In the present study, we have used aromatic hydroxylation of Phe to detect -OH formation in postischemic canine myocardium, the first time, to our knowledge, that this assay has been used in vivo. The results demonstrate that reperfusion following a brief episode of regional myocardial ischemia is associated with a burst of release of o-and m-tyr, which are specific products of OH attack on Phe. The release of tyrosines was markedly inhibited by MPG alone or combined with . o-Tyrosine indicates ortho-tyrosine; m-tyrosine, meta-tyrosine; and p-tyrosine, para-tyrosine. Infusion of MPG alone (group II) decreased the cumulative production of o-tyrosine and m-tyrosine by 68% and 80%o, respectively, as compared with group I. Combined administration ofMPG, superoxide dismutase, catalase, and desferrioxamine (group III) effected a near-complete inhibition of o-tyrosine production and a marked decrease of m-tyrosine production. However, the administration of these antioxidants did not significantly change the production of p-tyrosine (P>.05 among the three groups). The cumulative production of o-tyrosine was significantly lower in group III as compared with group II (P<.05), whereas the production of m-tyrosine did not differ between these two groups. Data are mean+SEM. "Reperfusion" SOD, catalase, and desferrioxamine, indicating that minantioxidant agents are capable of effectively scavenging from OH or preventing its generation in vivo. When tyrosine gene release was inhibited by antioxidant therapy, the con-indic comitant postischemic contractile derangements were cent, diminished, indicating that the formation of -OH is ning necessary for the development of severe myocardial Si: stunning. Phe, which itself acts as an -OH scavenger, inco: attenuated postischemic dysfunction. Taken together, a spe these results provide direct evidence supporting the m-ty hypothesis that -OH plays a significant role in vivo in the thern pathogenesis of the persistent myocardial dysfunction can observed after reversible ischemia (myocardial stun-vivo. ning). Previous investigations16-2332-35,59 have docu-of h: mented -OH generation in isolated buffer-perfused onsti hearts subjected to global ischemia. However, to our p-tyi knowledge, this is the first study to demonstrate that (1) or C -OH is produced after regional ischemia in vivo; ( (Fig 1) . All three syste tyrosine isomers are expected to be present in Phecontaining systems that are subject to -OH generation, Effea and the yields of the three isomers do not normally and differ by a factor greater than 239 (although the yield of PI p-tyr may be greater if it is also formed enzymatically). extre This concept is consistent with our finding that all three radii isomeric tyrosines were released in roughly comparable rosines in group IV (control group for tyrosine production, n=6). In these dogs, phenylalanine (Phe) was infused as in groups I, II, and III, but no coronary occlusion was performed. There was no appreciable myocardial production of ortho-, meta-, or para-tyrosine during the infusion ofPhe, ie, during the time interval corresponding to thefirst 10 minutes of reperfusion in groups I, II, and III. The production of para-tyrosine (a normal enzymatic product ofPhe) increased in the late phase of the experiment. B indicates baseline; "Occl," time corresponding to coronary occlusion in groups I, II, and III; and "reperfusion, " interval corresponding to the reperfusion phase in groups I, II, and III.
Data are mean+±SEM.
-1 g1, respectively). It is not possible to determine i our data what fraction of the total pool of -OH rated was trapped by Phe; however, our results cate that Phe intercepted a sufficiently large perage of -OH radicals to attenuate myocardial stun- (Fig 8) . rnce p-tyr is a normal metabolite of Phe that is rporated into proteins, it would not be suitable as ecific marker of -OH production. However, o-and Tr are not normal metabolites of Phe153139A0A243; efore, these "unnatural" hydroxylated products be used as biomarkers of -OH production in . 15 (MPG alone [group II]) and the other aimed both at scavenging -OH and at preventing its formation (MPG combined with SOD, catalase, and desferrioxamine [group III]). Since -OH is thought to be formed from *°2and H202 through the iron-catalyzed Haber-Weiss reaction,62 we reasoned that administration of SOD and catalase (which scavenge *°2and H202, respectively) and desferrioxamine (which chelates iron) should prevent the generation of -OH by removing all of the components of the Haber-Weiss chemistry. Therefore, combined therapy with MPG, SOD, catalase, and desferrioxamine should decrease -OH-mediated damage more efficiently than MPG alone. We used this therapy in an attempt to achieve "maximal" protection against -OH, so that the pathogenetic contribution of this species to myocardial stunning could be fully evaluated. Both of our therapeutic strategies were quite effective in diminishing -OH formation, but as expected, the combination of MPG, SOD, catalase, and desferrioxamine was superior to MPG alone. Although myocardial production of m-tyr was inhibited to a similar extent by the two treatments, the combination of antioxidants (group III) virtually abolished the production of o-tyr, whereas MPG alone (group II) decreased it by 68%, a difference that was statistically significant. (One may have expected the differences between group II and group III to be larger, but it must be noted that MPG alone prevented most of the tyrosine production in group LI [Fig 6] .) The effects of the two treatments on tyrosine production were accompanied by significant effects on postischemic recovery of contractile function: at 4 hours of reperfusion, systolic thickening fraction was increased from 33±11% of baseline in group I (Phe only) to 55 ±3% in group II (Phe+MPG) and to 65±7% in group III (Phe+combined therapy) (Fig 8) (P<.05 between group III and group I). These findings suggest an inverse relation between *OH activity and severity of myocardial stunning; ie, the greater the availability of -OH in the myocardium soon after reperfusion, the greater the subsequent depression of contractile function.
Nevertheless, it must be pointed out that myocardial stunning was not completely eliminated by the combined administration of MPG, SOD, catalase, and desferrioxamine. In dogs receiving this therapy (group III), thickening fraction was still depressed throughout the 4-hour reperfusion period, averaging 33±17% of baseline at 1 hour and 65±7% at 4 hours (Fig 8) . To our knowledge, this is the first demonstration that a "broad spectrum" multipharmacological approach targeted at *02, H202, -OH, and iron (the major species thought to be responsible for oxidative damage during reperfusion) does not ablate postischemic dysfunction. The failure of "maximal" antioxidant therapy to completely prevent myocardial stunning can be interpreted in at least two ways. First, our doses of MPG, SOD, catalase, and desferrioxamine may not have completely inhibited free radical reactions in the ischemic/reperfused myocardium. Although we found o-tyr production to be almost completely suppressed in group III, m-tyr was still being produced to some extent (Fig 6) , and more importantly, we did not measure free radical species other than OH. Second, myocardial stunning is likely to be a multifactorial phenomenon that involves the interaction of different pathogenetic mechanisms.' Even if oxyradical formation is completely prevented, postischemic dysfunction will still develop to a certain extent because of the damage inflicted by other factors (eg, calcium overload63). We believe both of these interpretations to be plausible. In any case, our results provide evidence that, although -OH plays an important role in myocardial stunning, it should be not be considered the sole culprit.
Previous Studies
Numerous previous studies using spin trapping with DMPO16-23 or aromatic hydroxylation with salicy-late32-35 have demonstrated production of -OH in isolated buffer-perfused hearts subjected to ischemia and reperfusion. In general, the time course of -OH adduct release noted in these investigations was consistent, with a peak occurring within the first 2 to 3 minutes of reperfusion and a marked decline or complete cessation within 10 minutes of reflow. Although these observa-tions16-23,32-35 have provided important insights into the role of -OH in myocardial ischemia/reperfusion injury, * P<0.05, **P<O.O1 vs Group I * Pc0.05, SPc0.01 vs Group V a a -/A a a a a a they cannot necessarily be extrapolated to the setting of the stunned myocardium for various reasons. First, the heart perfused with blood and subjected to regional ischemia in vivo differs in many important respects from the heart perfused with buffers and subjected to global ischemia in vitro. Furthermore, the models used in the aforementioned experiments16-23,32-35 have not been shown to be associated with stunned myocardium, which is defined as a persistent but completely reversible depression of contractility.64 Given that the duration of ischemia in these studies16-23,32-35was at least 20 minutes (usually 30 minutes or longer) (with the exception of the study by Takemura et a135 discussed below), it is likely that significant irreversible injury (cell death) occurred. Our finding that suppression of *OH formation results in enhanced functional recovery differs from the observations recently reported by Takemura et a135 in isolated rat hearts subjected to 15 minutes of ischemia and 30 minutes of reperfusion. Using salicylate as a probe for *OH, these authors found no correlation between the amount of 2,5-dihydroxybenzoic acid (2,5-DHBA) released (an index of -OH production) and various parameters of myocardial injury, including functional recovery, release of lactate dehydrogenase, and morphological assessment of cellular damage. Furthermore, addition of desferrioxamine to the buffer markedly suppressed the release of 2,5-DHBA but did not affect any parameter of myocardial injury. The authors concluded that, although *OH is produced in ischemic/reperfused myocardium, it is not produced in amounts sufficient to cause damage. 35 Besides the obvious differences in models (isolated hearts vs anesthetized dogs), there are several possible explanations for the apparent discrepancy between these results and our present findings. First, it appears that the 15-minute period of ischemia used by Takemura et al resulted in some degree of irreversible injury, as indicated by the increased release of lactate dehydrogenase and by the evidence of damage on ultrastructural analysis. Accordingly, the observation that *OH production did not correlate with enzyme leakage or with morphologic changes (two likely manifestations of irreversible injury)35 does not directly contradict our present observation that -OH formation correlates with postischemic dysfunction (a manifestation of reversible injury). Second, the degree of functional deterioration noted by Takemura et al was probably too small for a correlation with 2,5-DHBA release to be demonstrable. For example, positive dP/dt recovered to 91±6% of baseline in the absence of desferrioxamine, so there was little room for improvement with antioxidant therapy. The fact that most hearts recovered to .80% of baseline dP/dt would make it difficult to detect a significant relation between -OH production and postischemic dysfunction. Finally, it is possible, as indicated by the authors,35 that the small fraction of *OH radicals trapped by salicylate may not be critical to the development of injury, whereas the larger, untrapped fraction may inflict significant damage. This speculation is supported by the finding that salicylate failed to improve functional recovery. 35 (In contrast, in the present investigation we found that Phe mitigated myocardial stunning, implying that the OH radicals trapped by this amino acid play a significant role in the genesis of the contractile derangements.) In summary, we believe that the apparent present findings is due to differences in experimental techniques and/or in the type of injury examined.
Attenuation of Myocardial Stunning by Phe
The finding that Phe in itself enhanced postischemic recovery of function is important because it implies that the *OH radicals trapped by this agent play a pathogenetic role in the development of myocardial stunning. Accordingly, the present results suggest that the technique of aromatic hydroxylation of Phe enables not only the detection of *OH production but also the quantification of a pool of *OH radicals that is pathophysiologically relevant. A previous study in rats65 demonstrated that intravenous administration of Phe significantly improves the survival of skin flaps, a process linked to free radical formation. However, to our knowledge, this is the first report of a protective action of Phe in myocardial ischemia/reperfusion injury. The fact that Phe was infused starting 90 seconds before the release of coronary occlusion indicates that this amino acid can exert beneficial effects against myocardial stunning even when given just before reperfusion.
Methodological Implications
As mentioned earlier, the development of methods for quantitating *OH in whole animals could facilitate the evaluation of the role of this species in myocardial ischemia/reperfusion injury. The present study suggests that aromatic hydroxylation of Phe is a useful technique to measure *OH in vivo. The results obtained in groups II and III indicate that this method is sensitive to the effect of agents targeted at *OH and thus can be used to assess the effects of antioxidants in a quantitative manner. The fact that Phe had no apparent toxic effect on the cardiovascular system and was rapidly cleared from the circulation indicates that it can be administered safely and that serial infusions in the same experiment should not have a cumulative effect. Importantly, changes in -OH formation detected with this technique correlated with changes in recovery of function, implying that Phe intercepts a population of -OH radicals that contributes to tissue injury. Thus, aromatic hydroxylation of Phe could provide a useful tool to explore the pathogenesis of myocardial ischemia/reperfusion injury in vivo and perhaps of other forms of tissue injury in which *OH has been implicated. This technique may also be potentially applicable to the clinical setting to investigate the role of *OH in human disease states.
Conclusions
The results of this investigation demonstrate that aromatic hydroxylation of Phe can be used as a sensitive method to detect and quantitate production of -OH in vivo. By applying this method to our canine model of postischemic dysfunction, we have obtained direct evidence that -OH is an important mediator, but probably not the only mediator, of myocardial stunning. assistance during the course of these studies and Valerie R. Price for expert secretarial assistance.
